API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
KWA 0711 (mizagliflozin) is an investigational first-in-class, oral, SGLT1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): Mizagliflozin
Therapeutic Area: Endocrinology Product Name: KWA 0711
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
KWA-0711 (mizagliflozin) is a novel first in class SGLT1 inhibitor, small molecule therapeutic candidate. It is being evaluated for the treatment of post-bariatric hypoglycemia.
Lead Product(s): Mizagliflozin
Therapeutic Area: Endocrinology Product Name: KWA-0711
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
Mizagliflozin Encapsulated or Liquid Formulation is a novel first in class small molecule therapeutic candidate being developed for Post-Bariatric Hypoglycemia.
Lead Product(s): Mizagliflozin
Therapeutic Area: Endocrinology Product Name: VGX-3235
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023